Reduced Toxicity FluBu3 Regimen Showed a Comparable Post-Transplant Outcomes to a Myeloablative BuCy Conditioing in Acute Myeloid Leukemia Patients …
S Park, D Kwag, SY Bang, JH Lee, GJ Min, SS Park… - Blood, 2022 - ashpublications.org
Introduction: In a previous report, we found that post-transplant clinical outcomes were not
significantly different between MAC (BuCy, CyTBI) and RIC (FluBu2TBI400) groups in AML …
significantly different between MAC (BuCy, CyTBI) and RIC (FluBu2TBI400) groups in AML …
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell …
S Park, SY Bang, D Kwag, JH Lee, TY Kim… - Bone Marrow …, 2024 - nature.com
In the present study, reduced toxicity (FluBu3) and myeloablative (BuCy) conditioning were
compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1 …
compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1 …
[HTML][HTML] Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell …
SS Patel, L Rybicki, A Emrick, V Winslow, J Starn… - Blood, 2018 - Elsevier
Background Myeloablative conditioning (MAC) is a standard approach for allogeneic
hematopoietic cell transplantation (alloHCT), but is associated with risks of morbidity and …
hematopoietic cell transplantation (alloHCT), but is associated with risks of morbidity and …
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in …
The optimal intensity of conditioning for allogeneic hematopoietic stem cell transplantation
(HCT) in acute myeloid leukemia (AML) remains undefined. Traditionally, myeloablative …
(HCT) in acute myeloid leukemia (AML) remains undefined. Traditionally, myeloablative …
[PDF][PDF] Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute …
L Raida, P Tucek, E Faber… - Biomed Pap Med …, 2011 - biomed.papers.upol.cz
Aims. This study compares the outcomes of patients with high-risk acute myeloid leukemia
(AML) who underwent allogeneic stem cell transplantation (SCT) after conditioning …
(AML) who underwent allogeneic stem cell transplantation (SCT) after conditioning …
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with …
Methods In order to analyse the impact of the conditioning regimen we retrospectively
compared the outcome of adult patients with AML in CR1 that received an ASCT from 2010 …
compared the outcome of adult patients with AML in CR1 that received an ASCT from 2010 …
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete …
H Liu, X Zhai, Z Song, J Sun, Y Xiao, D Nie… - Journal of hematology & …, 2013 - Springer
Objective We conducted a prospective, randomized, open-label, multicenter study to
compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as …
compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as …
Comparison of conditioning regimens BU-CY and FLU-BU12-TG used in the patients undergoing allogeneic stem cell transplantation (SCT) for acute myeloid …
L Raida, P Tucek, J Vondrakova… - Biology of Blood and …, 2011 - tctjournal.org
Results No significant differences were found between the BU-CY and FLU-BU12-TG in the
incidence of acute (38% vs. 50%; P0, 53) or chronic GVHD (44% vs. 33%; P0, 58), AML …
incidence of acute (38% vs. 50%; P0, 53) or chronic GVHD (44% vs. 33%; P0, 58), AML …
[HTML][HTML] Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in patients allografted in remission for acute myeloid …
Introduction: Clofarabine/busulfan based reduced conditioning regimens (RIC) have been
developed recently with the hope to improve outcomes in older patients allografted for …
developed recently with the hope to improve outcomes in older patients allografted for …
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and …
Y Shimomura, M Hara, S Hirabayashi… - Bone Marrow …, 2021 - nature.com
The prognosis of refractory and relapsed acute myeloid leukemia (R/R AML) is dismal with
the 2-year overall survival (OS) being~ 20%[1]. Salvage chemotherapy alone offers almost …
the 2-year overall survival (OS) being~ 20%[1]. Salvage chemotherapy alone offers almost …